Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 7 years
- Director since
- 2023
7 years of board service in total across 2 boards, counting each seat separately. Longest: CytomX Therapeutics Inc., 3 years.
Chief executive roles
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Cardiff Oncology Inc. June 11, 2026100.0%
-
Cardiff Oncology Inc. June 26, 2025100.0%
-
CytomX Therapeutics Inc. June 11, 202569.5%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 14, 2026 | Cardiff Oncology Inc. | Open-market purchase | +34,364 | $1.46 | $50,171 |
| Jun 18, 2026 | Cardiff Oncology Inc. | Open-market purchase | +24,703 | $1.21 | $29,891 |
Questions about Mani Mohindru
What boards is Mani Mohindru on?
Mani Mohindru sits on the boards of Cardiff Oncology Inc. and CytomX Therapeutics Inc.
What company is Mani Mohindru the CEO of?
Mani Mohindru is Interim CEO of Cardiff Oncology Inc.
How long has Mani Mohindru served on boards?
Our records show at least 7 years of board service across 2 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.